ArticleAlpha psychiatry2026
Thalamic Subregion Alterations and Short-Chain Fatty Acids in Schizophrenia and Ultra-High-Risk Individuals: A Cross-Sectional Study.
Article in Alpha psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thalamic abnormalities have been implicated in schizophrenia, but their early role remains unclear. This study investigated structural and functional alterations of thalamic subregions in drug-naïve first-episode schizophrenia (FES) patients and ultra-high-risk (UHR) individuals, and explored their associations with serum short-chain fatty acids (SCFAs). Methods: This cross-sectional study included 102 FES patients, 72 UHR individuals, and 69 healthy controls (HCs). Structural magnetic resonance imaging (MRI) data were available for all participants, and functional MRI and SCFA measurements were conducted in subgroups (functional MRI (fMRI): 76 FES, 63 UHR, 61 HC; SCFA: 59 FES, 51 UHR, 40 HC). Results: Thalamic volume was smaller in FES compared to HCs, with atrophy present specifically at the psychotic stage, particularly affecting the right thalamus and nuclei including the mediodorsal medial magnocellular (MDm), ventromedial (VM), and ventral posterolateral (VPL). Functional connectivity (FC) disruptions were observed in the left sensory thalamus with cortico-striatal-thalamic circuits and in the right occipital thalamus with fronto-temporal regions. Thalamic volumetric deficits correlated with negative and disorganized symptoms in both clinical groups. Serum SCFAs showed several significant associations: in the UHR group, FC between the right occipital thalamus and the left medial frontal cortex was negatively associated with acetic acid and total SCFA levels; in FES patients, centromedian nucleus volume was positively correlated with acetic acid; and in HCs, butyric acid was inversely correlated with the volume of the mediodorsal (MD) lateral nucleus. Conclusions: These findings highlight early thalamic subregional alterations in psychosis risk and co-occurring changes in gut-derived metabolites. Whether and how these changes are related remains a question for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.